The biotech stock's price-to-earnings-to-growth (PEG) ratio is a super-low 0.58, according to the London Stock Exchange Group (LSEG). Any PEG ratio below 1.0 is viewed as an attractive valuation.
IBBQ is a relatively new US biotech ETF that competes with established peers like IBB and XBI. Read why I don't recommend ...
While it may not be among the industry's most popular ETFs, there's better-than-average performance to tap into here.